Karyopharm initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Karyopharm (KPTI) with an Overweight rating. The firm cites its probability-weighted scenarios from the company’s Phase 3 SENTRY trial in myelofibrosis for the buy rating. It assigns a 70% probability of success. A “clean win” would reposition Karyopharm from “challenged MM player” to “frontline MF combo contender” which would result in significant upside for the shares, the analyst tells investors in a research note.